导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.24% | 2768/4773 |
| 近一周 | -1.82% | 2939/5465 |
| 近一月 | -3.43% | 2493/5421 |
| 近一季 | -6.42% | 2403/5231 |
| 近半年 | -2.18% | 2041/4920 |
| 近一年 | 1.38% | 2504/4394 |
| 近两年 | 44.48% | 1697/2954 |
| 近三年 | 27.78% | 1176/2253 |
| 成立以来 | 62.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.60% 3306/4961 |
11.73% 2302/5312 |
- - |
- - |
| 2025 | 19.58% 2206/4813 |
-0.91% 2457/3635 |
2.31% 1655/4076 |
17.86% 2418/4524 |
0.08% 2237/4813 |
| 2024 | 15.97% 857/3463 |
2.90% 670/2808 |
-1.00% 889/3014 |
16.71% 1372/3129 |
-2.47% 2094/3463 |
| 2023 | -7.53% 925/2656 |
4.55% 922/2280 |
-3.53% 815/2385 |
-2.15% 625/2515 |
-6.30% 1713/2655 |
| 2022 | -18.77% 751/2207 |
-13.69% 814/1919 |
6.90% 577/2016 |
-13.35% 888/2113 |
1.60% 1205/2208 |
| 2021 | 1.48% 671/1822 |
-2.22% 600/1255 |
5.92% 785/1330 |
-3.90% 664/1466 |
1.96% 737/1822 |
| 2020 | 38.86% 346/1250 |
-8.29% 595/1028 |
15.03% 519/1067 |
15.06% 238/1164 |
14.39% 279/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.99% 369/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 永赢沪深300ETF发起联接A VS. 长安沪深300非周期A(740101) |